OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone267-364-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.07 million
Profitability
Miscellaneous
Employees102
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.09. The business had revenue of $6.68 million for the quarter, compared to analyst estimates of $7.74 million. OptiNose had a negative return on equity of 102.10% and a negative net margin of 670.20%. View OptiNose's Earnings History.
When is OptiNose's next earnings date?
What price target have analysts set for OPTN?
4 Wall Street analysts have issued 12-month price targets for OptiNose's shares. Their forecasts range from $20.00 to $29.00. On average, they expect OptiNose's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 209.0% from the stock's current price. View Analyst Price Targets for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.
What are Wall Street analysts saying about OptiNose stock?
Here are some recent quotes from research analysts about OptiNose stock:
- 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (7/11/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented." (5/9/2019)
Has OptiNose been receiving favorable news coverage?
Press coverage about OPTN stock has been trending negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OptiNose earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for OptiNose.
Are investors shorting OptiNose?
OptiNose saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 9,618,200 shares, an increase of 5.0% from the July 31st total of 9,159,600 shares. Based on an average daily trading volume, of 232,100 shares, the days-to-cover ratio is presently 41.4 days. Approximately 60.6% of the shares of the stock are sold short. View OptiNose's Current Options Chain.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Opko Health (OPK), Radius Health (RDUS), Theravance Biopharma (TBPH), AnaptysBio (ANAB), BELLUS Health (BLUSF), Innoviva (INVA), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Athenex (ATNX), Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Spectrum Pharmaceuticals (SPPI).
What other stocks do shareholders of OptiNose own?
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 58)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Thomas E. Gibbs, Exec. VP & Chief Commercial Officer (Age 47)
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (6.47%), BlackRock Inc. (4.65%), Rice Hall James & Associates LLC (3.37%), Vanguard Group Inc. (1.79%), Wasatch Advisors Inc. (1.62%) and Kornitzer Capital Management Inc. KS (1.34%). Company insiders that own OptiNose stock include Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.
Which institutional investors are selling OptiNose stock?
OPTN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Parametric Portfolio Associates LLC, Rice Hall James & Associates LLC and Citadel Advisors LLC. View Insider Buying and Selling for OptiNose.
Which institutional investors are buying OptiNose stock?
OPTN stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., JPMorgan Chase & Co., Eversept Partners LP, Kornitzer Capital Management Inc. KS, Royal Bank of Canada, Charles Schwab Investment Management Inc. and A.R.T. Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $8.09.
How big of a company is OptiNose?
OptiNose has a market capitalization of $333.79 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.
What is OptiNose's official website?
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
